FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

FDA approves sBLA for BioThrax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

The FDA has approved Emergent BioSolution's sBLA for BioThrax, the company's anthrax vaccine. The new approval changes the number of total vaccinnations that must be administered. It now calls for five intramuscular doses of BioThrax at 0, 1, 6, 12 and 18 months, compared with the former schedule of six subcutaneous doses at 0, 2 weeks and 1, 6, 12, 18 months. Emergent said the CDC is still studying whether even fewer doses of the drug could be equally effective. When that data becomes available in 2009, Emergent may submite another sBLA to further reduce the number of required BioThrax injections.

"Today's announcement is an exciting milestone in our continued mission to advance BioThrax. We are pleased that the U.S. Government shares our commitment to enhancing this critical countermeasure. The CDC is to be applauded for their hard work and diligence throughout this important effort," said Emergent's president and COO Daniel Abdun-Nabi.

- here's Emergent's release

Related Articles:
Emergent wins $404M anthrax vax contract
Emergent inks $29.7M anthrax vax contract
Emergent accuses biotech execs of wrecking buyout pact


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Vaccine   Emergent BioSolutions   anthrax vaccine   FDA approval   BioThrax